Monday, February 5, 2024

Breaking CBD News: Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences (OTCQB: $PBIO) UltraShear Processing for Revolutionary Product Effectiveness; @ir_pressurebio @UncleBuds_Hemp

 

Breaking CBD News: Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences (OTCQB: $PBIO) UltraShear Processing for Revolutionary Product Effectiveness; @ir_pressurebio @UncleBuds_Hemp

 

Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond

 

Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition

 


SOUTH EASTON, Mass. - February 5, 2024 (Investorideas.com Newswire) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is hosting a teleconference today (Monday, February 5th, 4:30PM EST) to discuss the recent acquisition of natural health and wellness innovator Uncle Bud's ("UB"), as well as other on-going opportunities.

 

Read this in full at https://www.investorideas.com/news/2024/cannabis/02051PBIO-CBD-Body-Revive-Spray.asp

 

CBD Body Revive Spray



 

CBD Body Revive Spray All Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class, UltraShear-processed Nano CBD

...the first in a series of groundbreaking premium nanoemulsified products designed to meet the needs of consumers looking for the highest quality and performance in natural and effective wellness solutions. Click here for more info on Uncle Bud's Premium Collection.

In an exciting leap forward for natural wellness enthusiasts, Uncle Bud's Health and Wellness ("Uncle Bud's") is announcing the planned launch of its UltraShear-processed "Premium Collection" of state-of-the-art nanoemulsified products. The collection, highlighted by its flagship product - the CBD Body Revive Spray with 1200mg of Nano CBD - will be processed with PBIO's multi-patented UltraShear Technology™ (UltraShear™ or UST™), and is expected to redefine the standards of effectiveness and quality in CBD and other products. These products represent the pinnacle of innovation, quality, and commitment to natural, clean wellness solutions. The Premium Collection launch is expected on or before March 1, 2024.

 

Developed in collaboration with scientists from Uncle Bud's parent PBIO, the UltraShear-processed Premium Collection stands as a testament to Uncle Bud's dedication to harnessing the power of science to amplify the benefits of natural ingredients. By utilizing cutting-edge UltraShear Technology, Premium Collection products will offer unparalleled speed of absorption and delivery of active ingredient dosing payload more efficiently - for faster, more effective results.

 

Embodying Uncle Bud's commitment to safety and environmental responsibility, all UltraShear Premium Collection products will be crafted from 100% natural, clean ingredients, and GMO-free. This meticulous attention to detail guarantees customers receive the highest quality, most sustainable products available for integrating into their daily wellness routines.

 

For the launch of the new premium products, Uncle Bud's is inaugurating a new website category dedicated exclusively to the innovation and quality of the Premium Collection product line. The launch of the initial product - CBD Body Revive Spray with 1200 mg of Nano CBD for powerful, fast-acting relief in a convenient spray form - offers an essential addition in any wellness regimen and marks the beginning of a series of groundbreaking premium products designed to meet the needs of consumers looking for the highest quality and performance in natural and effective wellness solutions.

 

"We are incredibly excited to introduce the UltraShear-processed Premium Collection of innovative, nanoemulsified products to our customers," said Bruno Schiavi, President of Uncle Bud's. "This is a major milestone for us, combining the best of science and nature to create a product line that not only meets but sets a new benchmark for the highest standards of quality, purity, and effectiveness." Click here for more info on Uncle Bud's Premium Collection.

 

John Hollister, PBIO's Director of Sales and Marketing, added: "What an exciting time for all stakeholders in PBIO. With revenues of $5 million anticipated from Uncle Bud's in 2024, combined with revenues of $5 million anticipated from historical PBIO products/services, we believe total 2024 revenues could be 5X or more of our historical annual revenue."

 

Teleconference Information (click here for more conference call details)

  • Date: Monday, February 5, 2024. 4:30 pm ET (US).
  • Call-in Number: 888-267-2918 (code: 973092).

 

About Uncle Bud's

Launched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud's has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud's brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud's is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations - including the revolutionary performance breakthroughs delivered by PBIO's patented UltraShear™ processing platform. Uncle Bud's diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow On Social Media: @UncleBuds_Hemp.

 

Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

 

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBIO, Uncle Bud's, and this press release, please click on the following website links:
http://www.pressurebiosciences.com www.unclebudshemp.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Press Contacts

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content on our site. Disclosure More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

 



About Investorideas.com

https://www.investorideas.com/About/

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Thursday, February 1, 2024

Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds

  

Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds

Uncle Bud's 2024 Revenue Expected to Increase 3-Fold to Approximately $5 Million, Fueled by UltraShear Processed Nanoemulsion Product Introductions and Exciting New Market Opportunities

 


SOUTH EASTON, Mass. - February 1, 2024 (Investorideas.com Newswire) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced that the Company will host a teleconference to discuss the recent strategic acquisition of natural health and wellness innovator Uncle Bud's ("UB") in an all-stock transaction. In particular, the Company will discuss its current, in-process move to new, more efficient manufacturing space; the integration plan of the Uncle Bud's team and product offerings into PBIO; and the significant growth expected from new UltraShear processed nanoemulsion products, which are expected to catapult the Company's total revenue by 5X to about $10M in 2024.

Read this news, featuring PBIO in full at https://www.investorideas.com/news/2024/cannabis/02011PBIO-Investor-Call-Recent-Acquisition-Uncle-Buds.asp

 

UltraShear CBD Body Revive Spray



All Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class Nano CBD

Teleconference Information

  • Format: Company presentation followed by Q&A.
  • Date: Monday, February 5, 2024. 4:30pm ET (US).
  • Call-in Number: 888-267-2918 (code: 973092).
  • Replay: PBIO.Replay.020524

Transaction Significance

  • Transaction is expected to be immediately accretive and a major accelerator to PBIO's top line revenue growth.
  • Combined companies will be positioned to attract new growth investment, rapidly strengthen the balance sheet, accelerate PBIO's path to profitability in 2024, and catalyze PBIO's drive to uplist to NASDAQ/NYSE in 2024.
  • UB leadership are experts in branding, spokesperson management, and online/retail multimedia marketing.
  • UB will rapidly incorporate PBIO's best-in-class Nano-CBD into renowned and successful CBD product lines.
  • Senior management of UB/PBIO plan a dozen new nanoemulsion products for commercial release in 2024.
  • UB already markets and sells many products in health & wellness that expand well beyond Hemp and CBD.
  • UB continues building ongoing partnership with multi-Grammy award-winning Toni Braxton - highly successful marketing ambassador leaps to embrace combined PBIO/UB as continuing spokesperson.
  • UB enjoys strong following for leading hemp and CBD products, in extensive variety of high profile news outlets and magazines online over many years: https://www.unclebudshemp.com/press/.
  • UB currently boasts 70+ products, 865K on-line members, and enviable sales channels with leading large retailers.

Expected Financial Impact

  • Acquisition combines existing momentum and ready market execution power of Uncle Bud's, with revolutionary product breakthroughs in absorption and speed of action, enabled by PBIO's UltraShear nanoemulsions platform.
  • PBIO forecasts Uncle Bud's $1.6 million 2023 revenue tripling to approximately $5 million in 2024.
  • PBIO forecasts a 5-fold catapult forward in total Company revenues to approximately $10 million in 2024.

Transaction Terms
Please refer to the Form 8K filed on January 19, 2024.

About Uncle Bud's

Launched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud's has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud's brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud's is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations - including the revolutionary performance breakthroughs delivered by PBIO's patented UltraShear™ processing platform. Uncle Bud's diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow On Social Media: @UncleBuds_Hemp.

Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBIO, Uncle Bud's, and this press release, please click on the following website links:
http://www.pressurebiosciences.com www.unclebudshemp.com
Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content on our site. Disclosure More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

 



About Investorideas.com

https://www.investorideas.com/About/

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Monday, January 22, 2024

Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Announces Closing of Uncle Bud's Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales; @ir_pressurebio

  

Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Announces Closing of Uncle Bud's Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales; @ir_pressurebio

 

Merged Companies Will Introduce Revolutionary New Product Capabilities Across Multiple Major Market Sectors, Expecting 2024 Revenues of Over $10 Million, Then Accelerating in Future Years

 



 

SOUTH EASTON, Mass. - January 22, 2024 (Investorideas.com Newswire) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced the closing of its acquisition of natural health and wellness leader Uncle Bud's ("UB") in an all-stock transaction. Incorporating UB's 70+ already popular products, 865K member on-line community, existing sales channels online and with leading large retailers, enviable celebrity spokesperson relationships, and invaluable experience building successful consumer products businesses, PBIO will leverage and integrate the Company's revolutionary UltraShear™ technology (UltraShear™ or UST™) platform for further improved nanoemulsified products that deliver industry-leading speed of action, effective dosing payload delivery, and long-term stability. With these unique product improvement and differentiation capabilities, PBIO intends to redefine the basis of competition in multiple major market sectors, and to become a leading provider of topicals and other consumer products.

 

Read this news, featuring PBIO in full at https://www.investorideas.com/news/2024/cannabis/01221PBIO-Uncle-Bud-Acquisition-UltraShear-Nanoemulsions.asp

 


Toni Braxton

Multi-award-winning singer, songwriter, actress, and long-term Uncle Bud's advocate and spokesperson.

Transaction Terms

Under the terms of the transaction, PBIO acquired all assets and assumed selected liabilities of UB. In addition, the parties agreed to an earnout for additional shares of PBIO Common Stock based on the achievement of revenue and pre-tax income results in 2024. Upon closing, all employees of UB became employees of PBIO and UB became the Consumer Products Business Unit of PBIO. More definitive transaction terms will be included in the Company's upcoming SEC filings.

 

Significance of the Transaction

  • The transaction is expected to be immediately accretive and a major accelerator to PBIO's top line revenue growth.
  • The combined companies will be ideally positioned to attract new growth investment, rapidly strengthen their balance sheet, accelerate PBIO's path to profitability in 2024, and catalyze our drive to uplist to NASDAQ/NYSE.
  • The co-founders/senior management of UB are experts in branding, celebrity spokesperson management, and online and retail multimedia marketing.
  • UB will rapidly incorporate PBIO's best-in-class Nano-CBD into their already highly renowned and successful CBD products, for new market breakaway potential!
  • Senior management of UB and PBIO are already planning a dozen new products that they believe could be formulated and released in 2024, just using PBIO's existing UltraShear processed Nano CBD.
  • UB markets and sells many products in the health & wellness area that are unrelated to Hemp and CBD.
  • UB has an ongoing partnership with multi-Grammy award-winning Toni Braxton as a highly successful marketing ambassador - and Toni has announced that she is excited to continue as a PBIO/UB spokesperson going forward.
  • UB has been featured, as well as their hemp and CBD products, in an extensive variety of high profile news outlets and magazines online over the past several years: https://www.unclebudshemp.com/press/.

 

Expected Financial Impact

PBIO's President and CEO, Richard T. Schumacher, summarized: "This transaction combines the existing momentum and ready market execution power of Uncle Bud's with the pivotal scientific and product breakthrough of the UltraShear nanoemulsions processing platform for record-setting product performance and long-term stability. In 2024 alone, we are forecasting a 5-fold leap forward in PBIO revenues to over $10 million, but this is only a steppingstone towards revolutionary impact and sales growth that we expect to achieve across the nutraceuticals, cosmeceuticals, skincare, food/beverage, agrochemical, and other major markets in the following years."

 

Jeffrey N. Peterson, PBIO's Chairman, added: "Our Board and leadership team have carefully sought out this strategic combination of Uncle Bud's marketing skill and power to combine with PBIO's world class scientific innovation team. Specifically, this positions PBIO with a fast forward integration capability that will allow us to selectively set the timing and drive the pace of revolutionary change across multiple major markets. This rapid growth engine provides a central platform to leverage new growth capital, restructure and strengthen our balance sheet, and complete our drive to uplist to a national stock exchange in 2024."

 

About Uncle Bud's

Officially launched in September 2018 with one hero product, Uncle Bud's has experienced unequivocal growth. As a leader in the Hemp and CBD space, Uncle Bud's takes pride in being Made in America, GMO Free, Cruelty Free and Leaping Bunny Certiļ¬ed. The full range includes Hemp & CBD products for pain relief, skincare, personal care, and even pet care - all retailing under $45. To learn more about Uncle Bud's visit unclebudshemp.com as well as their associated Instagram: @UncleBuds_Hemp; Facebook: @UncleBuds_Hemp and Twitter: @UncleBuds_Hemp.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBIO, Uncle Bud's, and this press release, please click on the following website links:
http://www.pressurebiosciences.com www.unclebudshemp.com


Please visit us on Facebook, LinkedIn, and Twitter.

 

Press Contacts

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content on our site. Disclosure More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

 


 Investorideas.com potcasts - Listen to Investor Ideas Potcasts Cannabis News and Stocks on the Move

 

Check out our stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks plus the new psychedelic stock directory

 

 

Follow Pot stocks news - Get News Alerts on Marijuana Stocks

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp